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Transforming growth factor-b (TGF-b) signaling re-
quires the action of Smad proteins in association with
other DNA-binding factors and coactivator and core-
pressor proteins to modulate target gene transcription.
Smad2 and Smad3 both associate with the c-Ski and Sno
oncoproteins to repress transcription of Smad target
genes via recruitment of a nuclear corepressor complex.
Ski-interacting protein (SKIP), a nuclear hormone re-
ceptor coactivator, was examined as a possible modula-
tor of transcriptional regulation of the TGF-b-respon-
sive promoter from the plasminogen activator inhibitor
gene-1. SKIP augmented TGF-b-dependent transactiva-
tion in contrast to Ski/Sno-dependent repression of this
reporter. SKIP interacted with Smad2 and Smad3 pro-
teins in vivo in yeast and in mammalian cells through a
region of SKIP between amino acids 201–333. In vitro,
deletion of the Mad homology domain 2 (MH2) domain of
Smad3 abrogated SKIP binding, like Ski/Sno, but the
MH2 domain of Smad3 alone was not sufficient for pro-
tein-protein interaction. Overexpression of SKIP par-
tially overcame Ski/Sno-dependent repression, whereas
Ski/Sno overexpression attenuated SKIP augmentation
of TGF-b-dependent transcription. Our results suggest a
potential mechanism for transcriptional control of
TGF-b signaling that involves the opposing and compet-
itive actions of SKIP and Smad MH2-interacting factors,
such as Ski and/or Sno. Thus, SKIP appears to modulate
both TGF-b and nuclear hormone receptor signaling
pathways.
Transforming growth factor-b (TGF-b)1 superfamily mem-
bers are multifunctional cell-cell signaling proteins, which in-
clude the TGF-bs, bone-morphogenetic proteins (BMPs), ac-
tivins, and inhibins, mullerian-inhibiting substance and
growth differentiation factors (1). Members of this superfamily
mediate many key cellular events in growth and development
and are evolutionarily conserved from Drosophila to mammals
(2). TGF-b signaling requires the action of a family of DNA-
binding proteins called Smads, including TGF-b-specific
(Smad2 and Smad3), BMP-specific (Smad1, Smad5 and
Smad8), a common Smad4, and anti-Smads (Smad6 and
Smad7). TGF-b signals through sequential activation of two
cell surface receptor serine-threonine kinases, which phospho-
rylate Smad2 and/or Smad3. Phosphorylated Smad2 or Smad3,
together with Smad4, translocates into the nucleus where the
Smad heterodimer binds Smad-binding elements (SBEs) in
association with other nuclear factors in promoters of target
genes (1, 3, 4).
Recently it has been shown that Smad proteins also interact
with other nuclear factors such as c-Ski and the Ski-related
novel (Sno) protein and nuclear hormone receptors, including
the vitamin D receptor (VDR) to modulate TGF-b signaling
(5–10). Ski and Sno are involved in oncogenic transformation
and enhancement of muscle differentiation by blocking TGF-b
signaling (11–14). The mechanism of Ski/Sno repression of
TGF-b signaling appears to involve an interaction with a com-
plex consisting of the nuclear corepressor (N-CoR) and a his-
tone deacetylase enzyme (15, 16). N-CoR, and its related co-
repressor silencing mediator for retinoic acid and thyroid
receptors (SMRT), interact with a wide variety of other nuclear
factors to mediate transcriptional repression (17–19). Interest-
ingly, the Ski-interacting protein (SKIP) was initially identi-
fied in a two hybrid screen using v-Ski as a bait and was later
independently identified as a VDR- and CBF1-interacting fac-
tor (20–22). Thus, the recent observation that SKIP modulates
CBF1 and Notch-dependent signaling suggests that SKIP may
play a role in the regulation of a number of different and
distinct cellular signaling pathways (23).
As Ski and Sno can modulate TGF-b-dependent signaling, it
was of interest to determine whether SKIP could also modulate
the TGF-b-signaling pathway through interaction with the
Smad proteins. In this study, in contrast to Ski- and Sno-
mediated repression, SKIP augmented TGF-b-dependent tran-
scription. A region of SKIP, aa 201–333, appeared to be re-
quired for the Smad interaction. SKIP interacted in vitro and
in vivo with Smad3 and partially counteracted Ski- and Sno-
dependent repression, while Ski/Sno attenuated SKIP transac-
tivation of TGF-b signaling. These results suggest that SKIP
may play an opposite role to Ski and Sno in the control of
TGF-b-dependent transcription.
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MATERIALS AND METHODS
Plasmid Constructs—SKIP wild-type cDNA was PCR cloned with the
forward primer (59-GGG AAT TCC CGG GGT CTA GAA CCA CCA TGG
CGC TCA CCA GCT TTT TA-39) and reverse primer (59-GCG GGA TCC
CTA TTC CTT CCT CCT CTT-39). The PCR product was ligated into
pGEM-T Easy plasmid (Promega, Madison, WI) from which an EcoRI/
BamH1 insert was excised and subcloned into a modified GAL4AD
pACTII plasmid (pACTIIb) and the vector pSG5 (Stratagene, La Jolla,
CA). The pACTIIb plasmid was created by replacing the BglII
polylinker fragment of pACTII (CLONTECH, Palo Alto, CA) with the
double-stranded oligonucleotide: 59-GAT CTG TGA ATT CCC GGG
GAT CCG TCG ACC TA-39. The GAL4 DBD wild-type Smad-pBridge
yeast two hybrid constructs were made by EcoRI/XhoI digestion of
Smad2-, Smad3-, and Smad4-pcDNA3 plasmids (3) and MH2 (aa 400–
425 of hSmad3)-pBridge by PCR and subcloning of Smad cDNAs into
the EcoRI/SalI sites of pBridge (CLONTECH). The GST-MH2 construct
was made by cloning cDNA of PCR product into the EcoRI/XhoI sites of
modified pGEX-4T2 plasmid (Amersham Pharmacia Biotech). The
SKIP deletion constructs (aa 1–200, aa 1–333, aa 201–536, and aa
334–536) were made by PCR and cloned into the EcoRI/BglII site of
pACTIIb and the XbaI/BamH1 site of pCGN. The Sno cDNA was am-
plified by PCR using the forward primer 59-GCA ATC TAG AGA AAG
CCC ACA AGC AAA TTT CCC-39 and reverse primer 59-GCA AGG ATC
CCT ATT TTC CAT TTC CAT TTT TG-39 and the PCR product ligated
into the XbaI/BamHI site of pCGN. The GST-SKIP construct was
made by PCR and cloned into the EcoRI and SalI sites of pGEX-KG
(24). All PCR primer sequences not listed are available on request. All
constructs were sequenced by automated fluorescent sequencing and
confirmed to be in frame and correct. The wild-type SKIP-pCGN,
c-Ski-pMT2, GST-Smad3, Smad2-, Smad3-, and Smad4-pcDNA3 constructs
and the 3TP-Lux reporter have been described previously (3, 20, 25–27).
Yeast Two-hybrid Analysis—Yeast transformation was performed
using a lithium acetate transformation kit (BIO101, Vista, CA). Wild-
type SKIP-pACTII plasmid encoding the SKIP-GAL4-AD fusion protein
was transformed into the Y187 yeast strain and Smad2-, Smad3-,
Smad4-, and MH2-pBridge encoding the Smad-GAL4 DBD fusion pro-
teins were transformed into the opposite yeast mating strain, CG1945.
To co-express the two different fusion proteins, yeast matings were
performed (CLONTECH Yeast Handbook, PT3024-1). Yeast ligand ex-
periments were performed as described previously (28). b-Galactosidase
activity in protein lysates was measured with the Tropix Galactolight
chemiluminescence assay (PerkinElmer Life Sciences) using the
Berthold LB953 luminometer (Berthold, Bad Wildbad, Germany) and
expressed as relative light units. All results are shown as mean 6 S.E.
of at least three different yeast colonies, from at least two experiments,
and corrected for protein concentration (Bio-Rad protein assay).
Cell Culture and Reporter Assays—COS-1 African green monkey
kidney cells were grown in Dulbecco’s modified Eagle’s medium with 5%
fetal calf serum at 37o in 5% CO2. Cells were plated the day before
transfection in 24-well plates at a cell density of 2 3 104 cells/well.
Transfections was performed with FuGENE-6 transfection reagent
(Roche Molecular Biochemicals) as per the manufacturer’s instructions
using 1.5 ml of FuGENE with 0.75 mg of total DNA/well. Transfected
cells were left in FuGENE transfection reagent for 16–20 h, then
treated with TGF-b (Sigma) or vehicle (4 mM HCl and 1 mg/ml bovine
serum albumin) in 2% charcoal-stripped medium for 16–24 h. The
medium was then removed, and cells were lysed with 23 Promega lysis
buffer. Luciferase assays were performed in triplicate with the firefly
luciferase assay kit (Promega) and measured with a luminometer
(Berthold).
Glutathione-Sepharose Binding Assays—Expression of appropriately
sized GST-SKIP and GST-Smad3 wild-type or mutant fusion proteins
was confirmed by SDS-PAGE. GST-binding assays were performed in
triplicate with equal amounts of 35S-labeled SKIP, VDR, or luciferase as
a negative control (28). Bound proteins were resolved on 10% SDS-
PAGE gels and subjected to autoradiography. In vitro translation and
transcription was performed according to the manufacturer’s instruc-
tions (Promega) with [35S]methionine (Amersham Pharmacia Biotech).
Far Western and Immunoblot Analysis—Far Western analysis and
preparation of nuclear extracts were essentially as described previously
(5, 28). COS1 nuclear extracts overexpressing Smad3 were run on 10%
SDS-PAGE and electroblotted onto a polyvinylidene difluoride mem-
brane (Millipore, Bedford, MA). Proteins were denatured with 6 M
guanidine hydrochloride and renatured by the stepwise dilution of
guanidine hydrochloride. The Smad3 membrane was then blocked and
hybridized overnight at 4 °C with 20 mg of COS1 nuclear extracts
containing HA-SKIP. The filter was rinsed three times in HYB (20 mM
Hepes-KOH, pH 7.4, 75 mM KCl, 0.1 mM EDTA, 2.5 mM MgCl2, 1%
nonfat milk, 1 mM phenylmethylsulfonyl fluoride, and 1 mM dithiothre-
itol) and then probed with an anti-HA antibody (Roche Molecular Bio-
chemicals), which detected HA-SKIP, followed by probing with a anti-
mouse-HRP secondary antibody (Santa Cruz) prior to ECL
chemiluminescent detection (Amersham Pharmacia Biotech) and
autoradiography.
Electromobility Shift Assay (EMSA)—EMSA was performed with the
PE2 probe from the PAI-1 promoter (29), as described previously (10),
using in vitro translated 35S-labeled Smad3 and Smad4 with COS1
nuclear extracts overexpressing SKIP, Sno, or Ski.
RESULTS
SKIP Augments TGF-b-dependent Transcription—As Ski
and Sno interact directly with Smad proteins (Smad2 and
Smad3) to repress TGF-b-dependent transcription, the effects
FIG. 1. SKIP augments TGF-b-dependent transactivation in
mammalian cells. A, transient transfections of COS1 cells were per-
formed in 24-well plates with the 3TP-lux reporter (250 ng/well) and the
following expression plasmids as indicated: SKIP-pCGN and Smad2-,
Smad3-, and Smad4-pcDNA3. The 3TP-Lux reporter contains three
clusters of Smad-binding elements from the PAI-1 promoter and is
predominantly a Smad3-responsive promoter reporter. Cells were
treated with vehicle (M) or TGF-b ligand (f) (1 ng/ml). The total amount
of transfected DNA was kept constant by use of respective empty
vectors. The results are shown as the mean luciferase activity 6 S.E. of
three independent experiments performed in triplicate. B, SKIP inter-
acts in vivo with Smad2 and Smad3 in a yeast two hybrid system
through a domain between 201 and 333 aa. Deletional analysis of
SKIP-GAL4-AD as indicated followed by co-expression with wild-type
Smad2-, Smad3-, and Smad4-GAL4-DBD was performed as described
under “Experimental Procedures.” Results of b-galactosidase activity
are shown as mean 6 S.E. from three independent colonies obtained in
at least duplicate experiments and are corrected for protein levels
determined by the Bio-Rad protein assay. RLUs, relative light units. C,
SKIP domain between aa 201 and 333 enhances TGF-b transactivation
in mammalian cells. Transient transfections of COS1 cells were per-
formed as described in A with the 3TP-lux reporter and the
Smad3-pcDNA3 expression plasmid (100 ng) and wild-type SKIP-pCGN
or deletion constructs as indicated (50 ng). Cells were treated with
vehicle (M) or TGF-b ligand (f) (1 ng/ml). The results are shown as the
mean luciferase activity 6 S.E. of two independent experiments per-
formed in triplicate.
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of SKIP on the 3TP-lux TGF-b-responsive reporter construct
(27) were tested (Fig. 1). In COS1 cells this reporter responded
to TGF-b with a 4-fold increase in reporter activity, consistent
with these cells expressing endogenous Smad proteins (30).
Smad3 alone, or Smad2 and Smad4 together (but neither
alone) augmented both basal (2-fold) and TGF-b responses
(10-fold) of this reporter activity. Smad3 co-transfection with
Smad4 led to a 6-fold increase in basal and a 30-fold increase in
ligand-dependent reporter activity. This augmentation was
similar to that of SKIP alone on ligand-dependent reporter
activity (Fig. 1). An interaction between SKIP and Smads was
suggested in co-transfection studies, with the -fold increase of
basal activity progressively increasing when SKIP was co-
transfected with Smad2 (8-fold), Smad2 and 4 (20-fold), Smad3
(53-fold), and Smad3 and Smad4 (164-fold). The comparable
increases in TGF-b induced activity were 39-, 116-, 96-, and
323-fold, respectively. These data are consistent with a func-
tional interaction primarily occurring between SKIP and
Smad3, with or without exogenous Smad4.
Mapping of SKIP-Smad Interaction Domains in Yeast and
Mammalian Cells—SKIP interaction with Smad proteins was
investigated by yeast two-hybrid interaction analysis. SKIP
interacted with both Smad2 and Smad3 (Fig. 1B). Smad4 in-
duced a high level of reporter activity, which was unaltered by
co-expression of SKIP. However, Smad4, as expected, inter-
acted strongly with v-Ski-GAL4-AD in yeast (data not shown).
Domains of SKIP required for Smad interaction were examined
using deletion constructs of SKIP (Fig. 1B). The C-terminally
deleted aa 1–333 and N-terminally deleted aa 201–536 SKIP
mutants had interaction with Smad2 comparable to that of
wild-type SKIP. The interaction between these two mutants
and Smad3 were about 50% and 25% of wild-type SKIP, respec-
tively. No interaction of the SKIP N-terminal (aa 1–200) or
C-terminal (aa 334–536) domain with Smad2 or Smad3 was
observed. Thus, these results suggest that the region of SKIP
between aa 201 and 333 interacts with Smad2 and Smad3.
The same SKIP deletion constructs were tested with the
3TP-lux reporter in the COS1 mammalian cell line (Fig. 1C).
Co-expression of wild-type SKIP (aa 1–536) with Smad3 caused
a synergistic 3-fold increase in reporter activity above SKIP or
Smad3 alone. The N-terminal domain of SKIP (aa 1–200) had
no effect on reporter activity, while the other SKIP constructs
had comparable transactivation to that of wild-type SKIP.
Western blot analysis of these deletion constructs showed com-
parable expression with wild-type, except for the aa 1–200
construct, which, despite its lack of transactivation, was 2–3
times more highly expressed (data not shown). Thus, these
transfection data were consistent with the yeast interaction
data and suggest that expression of the aa 201–333 region of
SKIP with Smad3 is sufficient for near maximal transactiva-
tion of the 3TP-lux reporter. Surprisingly, the aa 334–536
SKIP construct was able to activate the 3TP-lux reporter with
Smad3, even though no interaction was observed with Smad3
in yeast. This suggests that an additional C-terminal domain
may also be transcriptionally functional and possibly recruits
other Smad-interacting co-factors present in mammalian cells,
but not yeast.
SKIP Interaction with Smad2 and Smad3 in Vitro—The
potential direct physical interaction between the Smad pro-
teins and SKIP was explored using a GST “pull-down” assay.
GST-SKIP bound both Smad2 and Smad3 (Fig. 2A). In compar-
ison there was minimal, if any, binding of Smad2 or Smad3 to
GST-0 and no binding of luciferase to GST-SKIP.
To determine which domains of Smad3 may be involved in
SKIP interaction, a GST-Smad3 binding assay was performed
with 35S labeled in vitro translated SKIP (Fig. 2B). GST-wild-
type Smad3 bound SKIP and the positive control VDR (9).
Deletion of the MH1 domain of Smad3 (aa 199–427) had no
effect on SKIP binding, but, as expected, VDR binding was
abolished. Both SKIP and VDR binding was lost when both the
MH1 and MH2 domains of Smad3 were deleted (GST-Smad3
aa 199–405). However, no binding of SKIP was observed to a
GST-MH2 construct, which expressed only the last 26 aa of
hSmad3. This result was further supported by a lack of inter-
action between SKIP-GAL4-AD and a MH2-GAL4-DBD con-
struct containing the same C-terminal 26 aa of hSmad3 in vivo
in yeast (data not shown). These results indicate that, although
deletion of the C-terminal MH2 domain abrogates SKIP bind-
ing, the MH2 domain alone is not sufficient for SKIP
interaction.
To further support the existence of a direct protein-protein
interaction in vitro, a Far Western assay was performed using
mammalian cell nuclear extracts overexpressing HA-SKIP (up-
per panel) or Smad3 (middle panel) (Fig. 2C). In the Far West-
ern analysis (lower panel), Smad3 detected by Western analy-
FIG. 2. SKIP interacts with Smad2 and Smad3 in vitro. A, glu-
tathione-Sepharose beads were coated with bacterially expressed GST-
SKIP wild-type fusion proteins or GST alone and were incubated with
equal amounts of 35S-labeled wild-type Smad3 and luciferase. Bound
proteins were resolved by SDS-PAGE. Input proteins show one-fifth of
loaded lysate. B, Sepharose beads were coated with bacterially ex-
pressed fusion proteins consisting of GST-Smad3 or deletion mutants of
Smad3, including an MH1 and MH2 domain double mutant (aa 199–
405) and a phosphorylated MH1 domain deletion mutant that retains
the MH2 (aa 199–425), a mutant containing the MH2 domain consist-
ing of the last 26 aa of the C terminus of Smad3 (aa 400–425), or GST
alone. Beads were incubated with equal amounts of 35S-labeled wild-
type SKIP, and hVDR (9) and luciferase as positive and negative con-
trols, respectively. Bound proteins were resolved on SDS-PAGE. Input
proteins show one-fifth of loaded lysate. C, Far Western analysis.
Twenty mg of nuclear extracts containing HA-SKIP (upper panel) or
Smad3 (middle panel) was detected by Western analysis. COS1 nuclear
extracts were prepared from cells transfected with the empty vector
pcDNA3 or pCGN (indicated by 2) or Smad3-pcDNA3 or HA-SKIP-
pCGN expression plasmid (indicated by 1). Proteins in the Smad3-
containing membrane were resolved on SDS-PAGE, electroblotted to a
polyvinylidene difluoride membrane, denatured, renatured with serial
dilutions of 6 M guanidine hydrochloride, and probed with an anti-HA
antibody (lower panel). On Far Western analysis anti-HA antibody
detected a band co-migrating with Smad3, but not the negative control
extract.
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sis co-localized with HA-SKIP detected by using an anti-HA
antibody, but not with the negative empty vector control ex-
tracts. These results together with the GST-binding studies
thus strongly support the existence of a protein-protein inter-
action in vitro between SKIP and Smad3.
Ski and Sno Competitively Inhibit SKIP-dependent Activa-
tion—The Smad3 transcriptional repressors, Ski and its re-
lated protein, Sno, are known to bind to the MH2 domain of
Smad3 (26). Since SKIP also interacts with Ski and Sno, we
tested whether SKIP modulates Ski/Sno repression of Smad3-
dependent transcription. As shown above, SKIP increased ba-
sal and TGF-b-dependent transactivation, particularly in the
presence of Smad3 (Fig. 3). Both Ski and Sno attenuated this
SKIP-dependent transactivation by about 80% and 40%, re-
spectively (Fig. 3). SKIP transactivation, either alone or with
Smad3, was repressed in a dose-dependent manner by co-
transfection with Ski. Sno had a similar but weaker effect (Fig.
4). These data suggest that SKIP and Ski/Sno may act as
counteracting regulators of the TGF-b transcriptional
response.
As Ski/Sno interact with both Smad3 and SKIP, one alter-
native possibility other than a competitive interaction between
these proteins is that they form a ternary complex. To address
this question, a gel shift analysis was performed (Fig. 5). Using
the PE-2 probe from the PAI-1 promoter, which binds a
Smad3/4 heterodimer (29) (Fig. 5, lane 2), we showed that, with
addition of increasing amounts of SKIP nuclear extracts, there
was augmentation of binding of a higher molecular weight
complex, which presumably contained SKIP and Smad3/4
(lanes 3–6). The addition of Sno nuclear extracts also led to
increased Smad3/4 binding with a similar mobility shift (lanes
9 and 10 and lanes 12 and 13). This complex was specific as it
was abrogated by addition of cold probe (lane 11). However, in
the presence of both SKIP and increasing Sno, although we
observed increased intensity of the upper complex, no further
supershift and hence no ternary complex was observed (lanes
7–10). Similar results were obtained using Ski-overexpressing
nuclear extracts (data not shown).
DISCUSSION
The Ski and Sno oncoproteins have been shown to negatively
modulate TGF-b signaling through an interaction with a N-
CoR repressor complex (15). As SKIP, a nuclear hormone re-
ceptor-interacting cofactor, also associates with both Ski and
Sno, this study was undertaken to determine the potential role
of SKIP in TGF-b signaling. In these studies SKIP augmented
TGF-b2dependent transcription and exhibited a direct inter-
action with Smad proteins. This SKIP-Smad interaction was
apparent both in vitro and in vivo, as demonstrated by GST
pull-down assays, Far Western analysis, and yeast two hybrid
protein-protein studies. The region between aa 201 and 333
within SKIP appeared to act as the Smad-interacting domain,
while, SKIP, like Ski and Sno, interacted with the MH2 domain
of Smad3. Moreover, Ski and Sno attenuated SKIP transacti-
vation, while SKIP partially counteracted Ski- and Sno-medi-
ated transcriptional repression.
FIG. 3. SKIP augments TGF-b-dependent transcription and
partially counteracts Ski- and Sno-dependent repression. Tran-
sient transfections of COS1 cells were performed with the 3TP-lux
reporter (250 ng), Smad3-pcDNA3 (100 ng), and increasing amounts of
wild-type SKIP-pCGN as indicated, with either c-Ski-pMT2 (A, 100 ng)
or Sno-pCGN (B, 100 ng) expression plasmids. Cells were treated with
vehicle (M) or TGF-b ligand (f) (1 ng/ml). The results are shown as the
mean luciferase activity 6 S.E. of triplicate wells relative to ligand-de-
pendent reporter activity of Smad3 transfection alone set at 1, and are
representative of three independent experiments.
FIG. 4. Ski and Sno attenuates SKIP augmentation of TGF-b-
dependent transcription. Transient transfections of COS1 cells were
performed with the 3TP-lux reporter (250 ng) and Smad3-pcDNA3 (100
ng), wild-type SKIP-pCGN (50 ng), and increasing amounts of either
c-Ski-pMT2 (A) or Sno-pCGN (B) expression plasmids as indicated.
Cells were treated with vehicle (M) or TGF-b ligand (f) (1 ng/ml). The
results are shown as the mean luciferase activity 6 S.E. of triplicate
wells relative to maximal ligand-dependent reporter activity with SKIP
and Smad3 co-transfection set at 10, and are representative of three
independent experiments.
FIG. 5. SKIP and Sno independently bind to Smad3/4 DNA
complexes. In vitro 35S-labeled Smad3 and Smad4 (2 ml each) with
COS1 nuclear extracts of SKIP and Sno were added, as indicated (ml),
with radiolabeled PE2 probe, a fragment of the PAI-1 promoter and
analyzed by gel shift assay. Lane 1 contains untranslated lysate and
lane 2 Smad3/4 lysate alone (lower arrow). The SKIP/Smad3/4 (lanes
3–6) and Sno/Smad3/4 higher molecular weight complexes (lanes 7–10)
are indicated by upper arrow. CP, cold probe (lane 11).
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The C-terminal MH2 domain of Smad2 and Smad3 has been
reported to be a key region involved in multiple protein-protein
interactions, including those with the coregulators CBP/p300
and the Smad repressors Ski and Sno (1). The N-terminal MH1
domain of the Smads confers only low affinity DNA binding to
a consensus SBE (1). Although natural TGF-b-responsive pro-
moters contain functional clusters of SBEs, other DNA-binding
factors, such as FAST-1, TFE3, and AP-1, as well as non-DNA
binding factors through protein-protein interaction with the
C-terminal MH-2 domain, are involved in determining the
specificity and direction of Smad target gene action (29, 31, 32).
As such, SKIP appears to play a role in augmentation of TGF-
b-specific Smad transcriptional activity via an interaction with
the MH2 domain of Smad3. Our data also suggest, as SKIP was
unable to interact with an isolated MH2 domain (last 26 aa) of
Smad3 in GST binding assays and yeast two-hybrid studies,
that other regions within the Smad proteins possibly within the
context of the whole Smad protein may also modulate Smad-
SKIP interaction.
Although SKIP was able to interact with Smad2 and Smad3
in yeast, SKIP co-transfection with Smad3 with or without
Smad4, led to the greatest increases in reporter activity in
mammalian cells, presumably because the 3TP-lux reporter is
Smad3-selective (27). Thus, as SKIP interacted with Smad2 in
vivo and in vitro, it is also possible that SKIP in mammalian
cells may be able to modulate TGF-b signaling through Smad2
in certain situations (30). Furthermore, in the transient trans-
fections we observed that Smad3 augmented basal reporter
activity, as previously described with this promoter (5), but this
activity was further increased by SKIP. Further studies will be
required to address the specific reasons for this effect of SKIP.
The deletional analysis of SKIP in yeast and mammalian
cells suggests that the aa 201–333 region of SKIP is required
for Smad interactions in vivo. However, some functional differ-
ences were observed between yeast and mammalian cells. Spe-
cifically, although the C-terminal SKIP construct (aa 334–536)
did not interact with Smad2 or Smad3 in yeast, its transacti-
vation activity in mammalian cells was comparable to wild-
type SKIP. A C-terminal transactivation domain of SKIP that
functions in mammalian cells, distinct from the Smad interac-
tion domain, is consistent with the domain C-terminal to aa
437 of murine SKIP (NcoA-62) being involved in vitamin D-de-
pendent transactivation (21).
As SKIP interacts with Ski/Sno and Smad3 and, in turn,
Ski/Sno interact with Smad3, to address the possibility that
these proteins form a ternary complex, we performed a gel shift
analysis using the PE2 probe from the PAI-1 promoter, as used
in the transient transfections. The EMSA clearly showed that
both SKIP and Ski/Sno alone formed a slightly higher migrat-
ing complex with Smad3/4. However, we did not observe the
formation of a ternary complex in the presence of all three
proteins. Thus, these data are consistent with the transient
transfection results, which suggests competition occurring be-
tween SKIP and Ski/Sno for Smad3 transactivation, but cannot
exclude the presence of a ternary complex forming between
these proteins.
In this study SKIP acted as a coactivator of TGF-b-depend-
ent transcription. SKIP similarly acts as a coactivator of nu-
clear hormone receptor-dependent transcription, but also as a
repressor of Notch signaling through its interaction with SMRT
and associated histone deacetylase enzyme proteins (21, 23).
These divergent effects of SKIP may depend on interaction of
SKIP with other, possibly cell-specific nuclear factors. For ex-
ample, SKIP converts CBF1 from a transcriptional repressor to
activator through switching its interaction between the core-
pressor SMRT and Notch 1C (23). In our study SKIP and
Ski/Sno modulated each other’s opposing transcriptional activ-
ities, raising the intriguing possibility that the relative cellular
expression of SKIP versus Ski or Sno may play a regulatory role
on TGF-b-dependent transcription and hence its effects on cell
growth and differentiation. Interestingly, the Smad-interact-
ing domain of SKIP (aa 201–333) appears to be also involved in
interaction with Ski and Sno.2 These results and those showing
that SKIP, like Ski/Sno, interacted with the MH2 domain of
Smad3 suggest that the opposing transcriptional effects of
SKIP and Ski/Sno may involve competition for Smad3 binding
between SKIP and c-Ski/Sno, and/or other Smad3 MH2-inter-
acting factors, such as with CBP/p300 (7, 33, 34). Thus, the
modulatory effects of SKIP through the MH2 domain poten-
tially increase the complexity and diversity of Smad-dependent
transcriptional effects. Furthermore, as SKIP and Ski/Sno in-
teract with each other and also with the related corepressors
N-CoR/SMRT, an additional mechanism could involve SKIP-
mediated derepression (1, 15, 20, 23). This may possibly occur
via SKIP sequestration of corepressors such as SMRT or N-CoR
from the Ski/Sno repressor complex, a mechanism similar to
that suggested for Hoxc-8 and Smad1 (35). Whatever the mo-
lecular mechanism of SKIP action, it is nevertheless clear that
SKIP plays a role in modulation of this important cellular and
signaling pathway.
In summary, our results support a model in which SKIP
positively modulates TGF-b-dependent-transcription and po-
tentially competes with other MH2-interacting factors, such as
c-Ski and Sno, to determine the transcriptional outcome of a
TGF-b-responsive target gene. This suggests a potential role
for SKIP in the regulation of TGF-b effects on cell growth and
differentiation.
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